All filters
Slidesets
PI based mono and dual-therapy- Bonaventura Clotet, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2017
Slidesets
The clinical significance of low level viremia during treatment with cART- Martin Markowitz, MD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2017
Slidesets
ARV toxicities and management- Fujie Zhang, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2017
Slidesets
ARV toxicities and management- Fujie Zhang, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2017
Slidesets
Adolescents and HIV: Guiding and Protecting the Vulnerable Population- Dushyantha Jayaweera, MD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2017
Slidesets
Adolescents and HIV: Guiding and Protecting the Vulnerable Population- Dushyantha Jayaweera, MD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2017
Meeting
Spanish HIV Clinical Forum 2017
Slidesets
Update on HIV Transmitted and Acquired Integrase Resistance in Spain - Relevance to Routine Clinical Practice- Federico García, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Prevalence of Transmitted Drug Resistance Mutations among Naïve HIV-infected patients (2014-2016) in Northwest Spain- B. Pernas Souto
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
2016-2017 - Key Advances in HIV Treatment- José Arribas, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Primary Resistance to Integrase Strand-Transfer Inhibitors in Spain, 2015-2016 - M. Casadellà
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Mutaciones a Inhibidores de la Integrasa en la vida real- I. Viciana
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. Viciana
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Pharmacological perspective- José Moltó, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Toxicity and co-morbidities perspective- José Ignacio Bernardino, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Virological perspective- Santiago Moreno, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
HIV Prevention 2.0- Charles Boucher, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-Torres
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. Mur
Presented at:
Spanish HIV Clinical Forum 2017